JPS58126878A - 新規の（フエニル−４ピペラジニルエチル）−２アニリン、その製法及び治療剤としての使用 - Google Patents
新規の（フエニル−４ピペラジニルエチル）−２アニリン、その製法及び治療剤としての使用Info
- Publication number
- JPS58126878A JPS58126878A JP57192340A JP19234082A JPS58126878A JP S58126878 A JPS58126878 A JP S58126878A JP 57192340 A JP57192340 A JP 57192340A JP 19234082 A JP19234082 A JP 19234082A JP S58126878 A JPS58126878 A JP S58126878A
- Authority
- JP
- Japan
- Prior art keywords
- product
- novel
- formula
- item
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 150000002828 nitro derivatives Chemical class 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- XETLOFNELZCXMX-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(4-hexoxyphenyl)-2-hydroxy-2-phenylacetate;hydrochloride Chemical compound Cl.C1=CC(OCCCCCC)=CC=C1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 XETLOFNELZCXMX-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- RIMRLBGNCLMSNH-UHFFFAOYSA-N 2-phenylpiperazine Chemical compound C1NCCNC1C1=CC=CC=C1 RIMRLBGNCLMSNH-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000006650 Syzygium cordatum Nutrition 0.000 description 1
- 240000005572 Syzygium cordatum Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- -1 phenyl-4-piperazinylethyl Chemical group 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8120564A FR2515648A1 (fr) | 1981-11-03 | 1981-11-03 | Nouvelles (phenyl-4 piperazinylethyl)-2 anilines, leur methode de preparation et leur application therapeutique |
| FR8120564 | 1981-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS58126878A true JPS58126878A (ja) | 1983-07-28 |
Family
ID=9263640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57192340A Pending JPS58126878A (ja) | 1981-11-03 | 1982-11-01 | 新規の（フエニル−４ピペラジニルエチル）−２アニリン、その製法及び治療剤としての使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4668681A (enExample) |
| EP (1) | EP0078756B1 (enExample) |
| JP (1) | JPS58126878A (enExample) |
| CA (1) | CA1210006A (enExample) |
| DE (1) | DE3269872D1 (enExample) |
| ES (1) | ES517096A0 (enExample) |
| FR (1) | FR2515648A1 (enExample) |
| MA (1) | MA19634A1 (enExample) |
| OA (1) | OA07244A (enExample) |
| PT (1) | PT75775B (enExample) |
| ZA (1) | ZA828044B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8619472D0 (en) * | 1986-08-09 | 1986-09-17 | Pfizer Ltd | Anti-arrhythmia agents |
| US5219855A (en) * | 1988-01-29 | 1993-06-15 | Mitsubishi Kasei Corporation | Anxiolytic drug |
| FR2632641B1 (fr) * | 1988-06-13 | 1990-10-12 | Irceba | ((aryl-4-piperazinyl-1)-2 ethoxy)-3 p-cymene, les derives ortho, meta, para monosubstitues ou disubstitues sur le noyau phenyle dudit produit, le procede de preparation desdits derives, et les medicaments contenant lesdits composes comme principe actif |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR78756E (fr) * | 1957-11-22 | 1962-09-07 | Système de sécurité incorporé pour charrue | |
| NL251385A (enExample) * | 1959-12-21 | |||
| GB971041A (en) * | 1960-02-02 | 1964-09-30 | May & Baker Ltd | New phenylpiperazine compounds |
| GB953005A (en) * | 1961-02-24 | 1964-03-18 | Soc Ind Fab Antibiotiques Sifa | Substituted n-phenylethyl-n-phenyl-piperazines |
| BE620235R (fr) * | 1961-07-14 | 1963-01-14 | May & Baker Ltd | Nouvelles pipérazines N-N disubstituéer |
| US3562277A (en) * | 1967-09-06 | 1971-02-09 | Shulton Inc | Ketonic derivatives of phenyl piperazines |
| DE2325633A1 (de) * | 1973-05-21 | 1974-12-12 | Boehringer Sohn Ingelheim | Piperazinderivate |
| US3981864A (en) * | 1973-09-08 | 1976-09-21 | Eisai Co., Ltd. | 1,3-Benzodioxol derivatives |
| US4094980A (en) * | 1974-09-03 | 1978-06-13 | Boehringer Ingelheim Gmbh | N-[1-(3',4'-methylenedioxy-phenyl)-propyl-(2)]-N'-phenyl-piperazines and salts thereof |
| FR2476644A1 (fr) * | 1980-02-21 | 1981-08-28 | Sarget Lab | Orthoarylydeneaminophenethylamine, leur preparation et leur utilisation therapeutique |
-
1981
- 1981-11-03 FR FR8120564A patent/FR2515648A1/fr active Granted
-
1982
- 1982-10-27 EP EP82450014A patent/EP0078756B1/fr not_active Expired
- 1982-10-27 DE DE8282450014T patent/DE3269872D1/de not_active Expired
- 1982-11-01 MA MA19846A patent/MA19634A1/fr unknown
- 1982-11-01 JP JP57192340A patent/JPS58126878A/ja active Pending
- 1982-11-02 PT PT75775A patent/PT75775B/pt not_active IP Right Cessation
- 1982-11-02 CA CA000414677A patent/CA1210006A/fr not_active Expired
- 1982-11-03 ZA ZA828044A patent/ZA828044B/xx unknown
- 1982-11-03 ES ES517096A patent/ES517096A0/es active Granted
- 1982-11-03 OA OA57837A patent/OA07244A/xx unknown
-
1986
- 1986-03-21 US US06/843,915 patent/US4668681A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT75775B (en) | 1985-07-26 |
| ES8307777A1 (es) | 1983-08-01 |
| PT75775A (en) | 1982-12-01 |
| US4668681A (en) | 1987-05-26 |
| CA1210006A (fr) | 1986-08-19 |
| EP0078756B1 (fr) | 1986-03-12 |
| FR2515648A1 (fr) | 1983-05-06 |
| ZA828044B (en) | 1983-08-31 |
| EP0078756A1 (fr) | 1983-05-11 |
| FR2515648B1 (enExample) | 1984-08-24 |
| ES517096A0 (es) | 1983-08-01 |
| OA07244A (fr) | 1984-04-30 |
| MA19634A1 (fr) | 1983-07-01 |
| DE3269872D1 (en) | 1986-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6156167A (ja) | 薬学的に活性なピペラジノ誘導体及びその製造法 | |
| JPS6236370A (ja) | チアジアジニル誘導体及びその製法 | |
| RU2003104821A (ru) | Новые производные фенилаланина | |
| JPS6089471A (ja) | ２‐アミノニトロピリジン誘導体及びその製造法 | |
| NL1010018C2 (nl) | Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. | |
| IT8348746A1 (it) | Derivati amminometil-benzenici arili-sostituiti ad attività regolatrice del ritmo cardiaco e composizioni che li contengono | |
| JPH04500373A (ja) | キノリン―３―カルボキシアニリドの誘導体 | |
| DE2623447A1 (de) | N-substituierte 2-methoxy-benzolsulfonamide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| JPS58126878A (ja) | 新規の（フエニル−４ピペラジニルエチル）−２アニリン、その製法及び治療剤としての使用 | |
| CA1219587A (en) | Hydroxybenzylaminobenzenes as anti-inflammatory agents | |
| JPH05504339A (ja) | 新規かつ強力な最終分化誘発剤及びその使用方法 | |
| JPS63196573A (ja) | キナゾリン酢酸誘導体 | |
| JPS59176265A (ja) | ピペラジニルアルカン化合物 | |
| JPS62132869A (ja) | キナゾリン誘導体、それらの製法、それらを含む薬剤及びその利用法 | |
| JPS6026154B2 (ja) | 塩基性オキサジン染料の製造法 | |
| DE2337023C3 (de) | Verfahren zur Herstellung von Aldehyden von 2-Hydroxynaphthalin-3-carbonsäurearylamiden | |
| US2419230A (en) | Therapeutic compositions and method of preparing same | |
| JPS60208949A (ja) | 新規ジアミン誘導体、その製法、及びその化合物を含有する医薬品 | |
| US3156699A (en) | Nu-(5-nitro-thiazolyl-2) 2, 4-dinitropyrrole-1-acetamide | |
| US2691657A (en) | 1-aza-8-methyl-9-thia-anthrones and their method of manufacture | |
| US2956081A (en) | N-amido-glycyclamides | |
| JPS591457A (ja) | ベンズヒドリルスルフイニルエチルアミン誘導体 | |
| US2662889A (en) | Tertiary-aminoalkyl 4-alkylamino-2-benzyloxybenzoates and debenzylation thereof | |
| JP2001519802A (ja) | ハロフラボノイド及び／又はニトロ置換フラボノイドの抗不安薬としての使用 | |
| JPH0329784B2 (enExample) |